The Risk of Malignancy Index (RMI) uses CA125 and clinical features to assess the chance of ovarian cancer.
It cannot be used to diagnose ovarian cancer.
It is used to plan the detail treatment of ovarian cyst.
ROMA test is a computer calculation involving clinical factors (age >18yrs) and blood values of HE4 (Human Epididymis Protein 4) and CA125. ROMA test assesses the possibility of finding cancer in an existing ovarian cyst. It is not meant to be used as a screening test for ovarian cancer. ROMA test carries the following FDA Black Box Warning:-
Women with strong family history of cancer and women with BRCA-1 or BRCA-2 gene mutation are advised to have ovarian screening. Strong family history refers to the following relations:
Screening for ovarian cancer involves CA125 and pelvic ultrasound every 4-6 months. Although screening cannot prevent ovarian cancer, they can possibly diagnose ovarian cancer earlier, hopefully at Stage 1. You can read more about ovarian cancer screening by downloading this article "Cancer and the Ovaries. Understanding ovarian cancer and screening methods"